165 related articles for article (PubMed ID: 37246588)
1. Treatment-free remission after dasatinib in patients with chronic myeloid leukaemia in chronic phase with deep molecular response: Final 5-year analysis of DASFREE.
Shah NP; García-Gutiérrez V; Jiménez-Velasco A; Larson SM; Saussele S; Rea D; Mahon FX; Levy MY; Gómez-Casares MT; Mauro MJ; Sy O; Martin-Regueira P; Lipton JH
Br J Haematol; 2023 Sep; 202(5):942-952. PubMed ID: 37246588
[TBL] [Abstract][Full Text] [Related]
2. Dasatinib discontinuation in patients with chronic-phase chronic myeloid leukemia and stable deep molecular response: the DASFREE study.
Shah NP; García-Gutiérrez V; Jiménez-Velasco A; Larson S; Saussele S; Rea D; Mahon FX; Levy MY; Gómez-Casares MT; Pane F; Nicolini FE; Mauro MJ; Sy O; Martin-Regueira P; Lipton JH
Leuk Lymphoma; 2020 Mar; 61(3):650-659. PubMed ID: 31647335
[TBL] [Abstract][Full Text] [Related]
3. Discontinuation of dasatinib in patients with chronic myeloid leukaemia who have maintained deep molecular response for longer than 1 year (DADI trial): a multicentre phase 2 trial.
Imagawa J; Tanaka H; Okada M; Nakamae H; Hino M; Murai K; Ishida Y; Kumagai T; Sato S; Ohashi K; Sakamaki H; Wakita H; Uoshima N; Nakagawa Y; Minami Y; Ogasawara M; Takeoka T; Akasaka H; Utsumi T; Uike N; Sato T; Ando S; Usuki K; Morita S; Sakamoto J; Kimura S;
Lancet Haematol; 2015 Dec; 2(12):e528-35. PubMed ID: 26686407
[TBL] [Abstract][Full Text] [Related]
4. Treatment-free remission after first-line dasatinib discontinuation in patients with chronic myeloid leukaemia (first-line DADI trial): a single-arm, multicentre, phase 2 trial.
Kimura S; Imagawa J; Murai K; Hino M; Kitawaki T; Okada M; Tanaka H; Shindo M; Kumagai T; Ikezoe T; Uoshima N; Sato T; Watanabe R; Kowata S; Hayakawa M; Hosoki T; Ikeda K; Kobayashi T; Kakinoki Y; Nishimoto T; Takezako N; Shibayama H; Takaori-Kondo A; Nakamae H; Kawaguchi A; Ureshino H; Sakamoto J; Ishida Y;
Lancet Haematol; 2020 Mar; 7(3):e218-e225. PubMed ID: 31978329
[TBL] [Abstract][Full Text] [Related]
5. Final 3-year Results of the Dasatinib Discontinuation Trial in Patients With Chronic Myeloid Leukemia Who Received Dasatinib as a Second-line Treatment.
Okada M; Imagawa J; Tanaka H; Nakamae H; Hino M; Murai K; Ishida Y; Kumagai T; Sato S; Ohashi K; Sakamaki H; Wakita H; Uoshima N; Nakagawa Y; Minami Y; Ogasawara M; Takeoka T; Akasaka H; Utsumi T; Uike N; Sato T; Ando S; Usuki K; Mizuta S; Hashino S; Nomura T; Shikami M; Fukutani H; Ohe Y; Kosugi H; Shibayama H; Maeda Y; Fukushima T; Yamazaki H; Tsubaki K; Kukita T; Adachi Y; Nataduka T; Sakoda H; Yokoyama H; Okamoto T; Shirasugi Y; Onishi Y; Nohgawa M; Yoshihara S; Morita S; Sakamoto J; Kimura S;
Clin Lymphoma Myeloma Leuk; 2018 May; 18(5):353-360.e1. PubMed ID: 29610029
[TBL] [Abstract][Full Text] [Related]
6. Treatment-free remission after first-line dasatinib treatment in patients with chronic myeloid leukemia in the chronic phase: the D-NewS Study of the Kanto CML Study Group.
Yamaguchi H; Takezako N; Ohashi K; Oba K; Kumagai T; Kozai Y; Wakita H; Yamamoto K; Fujita A; Igarashi T; Yoshida C; Ohyashiki K; Okamoto S; Sakamoto J; Sakamaki H; Inokuchi K
Int J Hematol; 2020 Mar; 111(3):401-408. PubMed ID: 31894533
[TBL] [Abstract][Full Text] [Related]
7. Treatment-free remission after a second TKI discontinuation attempt in patients with Chronic Myeloid Leukemia re-treated with dasatinib - interim results from the DAstop2 trial.
Flygt H; Söderlund S; Richter J; Saussele S; Koskenvesa P; Stenke L; Mustjoki S; Dimitrijevic A; Stentoft J; Majeed W; Roy L; Wolf D; Dreimane A; Gjertsen BT; Gedde-Dahl T; Ahlstrand E; Markevärn B; Hjorth-Hansen H; Janssen J; Olsson-Strömberg U
Leukemia; 2024 Apr; 38(4):781-787. PubMed ID: 38278960
[TBL] [Abstract][Full Text] [Related]
8. Dasatinib rapidly induces deep molecular response in chronic-phase chronic myeloid leukemia patients who achieved major molecular response with detectable levels of BCR-ABL1 transcripts by imatinib therapy.
Shiseki M; Yoshida C; Takezako N; Ohwada A; Kumagai T; Nishiwaki K; Horikoshi A; Fukuda T; Takano H; Kouzai Y; Tanaka J; Morita S; Sakamoto J; Sakamaki H; Inokuchi K
Int J Clin Oncol; 2017 Oct; 22(5):972-979. PubMed ID: 28550414
[TBL] [Abstract][Full Text] [Related]
9. [Observational study of chronic myeloid leukemia Chinese patients who discontinued tyrosine kinase inhibitors in the real-world].
Zhao HF; Yang YF; Liu BC; Li WM; Xu N; Liu XL; Jiang Q; Dang HB; Liang LX; Zhang Y; Song YP
Zhonghua Xue Ye Xue Za Zhi; 2022 Aug; 43(8):636-643. PubMed ID: 36709147
[No Abstract] [Full Text] [Related]
10. De-escalation of tyrosine kinase inhibitor therapy before complete treatment discontinuation in patients with chronic myeloid leukaemia (DESTINY): a non-randomised, phase 2 trial.
Clark RE; Polydoros F; Apperley JF; Milojkovic D; Rothwell K; Pocock C; Byrne J; de Lavallade H; Osborne W; Robinson L; O'Brien SG; Read L; Foroni L; Copland M
Lancet Haematol; 2019 Jul; 6(7):e375-e383. PubMed ID: 31201085
[TBL] [Abstract][Full Text] [Related]
11. Importance of TKI treatment duration in treatment-free remission of chronic myeloid leukemia: results of the D-FREE study.
Yoshida C; Yamaguchi H; Doki N; Murai K; Iino M; Hatta Y; Onizuka M; Yokose N; Fujimaki K; Hagihara M; Oshikawa G; Murayama K; Kumagai T; Kimura S; Najima Y; Iriyama N; Tsutsumi I; Oba K; Kojima H; Sakamaki H; Inokuchi K;
Int J Hematol; 2023 May; 117(5):694-705. PubMed ID: 36739328
[TBL] [Abstract][Full Text] [Related]
12. Long-term follow-up of lower dose dasatinib (50 mg daily) as frontline therapy in newly diagnosed chronic-phase chronic myeloid leukemia.
Naqvi K; Jabbour E; Skinner J; Anderson K; Dellasala S; Yilmaz M; Ferrajoli A; Bose P; Thompson P; Alvarado Y; Jain N; Takahashi K; Burger J; Estrov Z; Borthakur G; Pemmaraju N; Paul S; Cortes J; Kantarjian HM
Cancer; 2020 Jan; 126(1):67-75. PubMed ID: 31553487
[TBL] [Abstract][Full Text] [Related]
13. Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study.
Rea D; Nicolini FE; Tulliez M; Guilhot F; Guilhot J; Guerci-Bresler A; Gardembas M; Coiteux V; Guillerm G; Legros L; Etienne G; Pignon JM; Villemagne B; Escoffre-Barbe M; Ianotto JC; Charbonnier A; Johnson-Ansah H; Noel MP; Rousselot P; Mahon FX;
Blood; 2017 Feb; 129(7):846-854. PubMed ID: 27932374
[TBL] [Abstract][Full Text] [Related]
14. Silent NK/T cell reactions to dasatinib during sustained deep molecular response before cessation are associated with longer treatment-free remission.
Kumagai T; Nakaseko C; Nishiwaki K; Yoshida C; Ohashi K; Takezako N; Takano H; Kouzai Y; Murase T; Matsue K; Morita S; Sakamoto J; Wakita H; Sakamaki H; Inokuchi K;
Cancer Sci; 2020 Aug; 111(8):2923-2934. PubMed ID: 32614159
[TBL] [Abstract][Full Text] [Related]
15. Rapid reduction in BCR-ABL1 transcript predicts deep molecular response in dasatinib-treated chronic-phase chronic myeloid leukaemia patients.
Murai K; Yamaguchi K; Ito S; Miyagishima T; Shindo M; Wakasa K; Inomata M; Nagashima T; Kondo T; Fujimoto N; Yamamoto S; Yonezumi M; Oyake T; Kowata S; Tsukushi Y; Mine T; Meguro K; Ikeda K; Watanabe R; Saito S; Sato S; Tajima K; Chou T; Kubo K; Oba K; Sakamoto J; Ishida Y;
Eur J Haematol; 2018 Jan; 100(1):27-35. PubMed ID: 28895203
[TBL] [Abstract][Full Text] [Related]
16. Sustained molecular response following a failed attempt of tyrosine kinase inhibitor discontinuation & the effects on growth in a child with chronic myeloid leukemia: not always a short story.
Triche L; Yarbrough A; Roth M; Ying A; Wells R
Pediatr Hematol Oncol; 2020 Aug; 37(5):375-379. PubMed ID: 32347770
[TBL] [Abstract][Full Text] [Related]
17. Second tyrosine kinase inhibitor discontinuation attempt in patients with chronic myeloid leukemia.
Legros L; Nicolini FE; Etienne G; Rousselot P; Rea D; Giraudier S; Guerci-Bresler A; Huguet F; Gardembas M; Escoffre M; Ianotto JC; Noël MP; Varet BR; Pagliardini T; Touitou I; Morisset S; Mahon FX;
Cancer; 2017 Nov; 123(22):4403-4410. PubMed ID: 28743166
[TBL] [Abstract][Full Text] [Related]
18. Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial.
Saussele S; Richter J; Guilhot J; Gruber FX; Hjorth-Hansen H; Almeida A; Janssen JJWM; Mayer J; Koskenvesa P; Panayiotidis P; Olsson-Strömberg U; Martinez-Lopez J; Rousselot P; Vestergaard H; Ehrencrona H; Kairisto V; Machová Poláková K; Müller MC; Mustjoki S; Berger MG; Fabarius A; Hofmann WK; Hochhaus A; Pfirrmann M; Mahon FX;
Lancet Oncol; 2018 Jun; 19(6):747-757. PubMed ID: 29735299
[TBL] [Abstract][Full Text] [Related]
19. Low-dose tyrosine kinase inhibitors before treatment discontinuation do not impair treatment-free remission in chronic myeloid leukemia patients: Results of a retrospective study.
Cayssials E; Torregrosa-Diaz J; Gallego-Hernanz P; Tartarin F; Systchenko T; Maillard N; Desmier D; Machet A; Fleck E; Corby A; Motard C; Denis G; Herbelin A; Gombert JM; Roy L; Ragot S; Leleu X; Guilhot F; Chomel JC
Cancer; 2020 Aug; 126(15):3438-3447. PubMed ID: 32459375
[TBL] [Abstract][Full Text] [Related]
20. The e13a2 BCR-ABL transcript negatively affects sustained deep molecular response and the achievement of treatment-free remission in patients with chronic myeloid leukemia who receive tyrosine kinase inhibitors.
D'Adda M; Farina M; Schieppati F; Borlenghi E; Bottelli C; Cerqui E; Ferrari S; Gramegna D; Pagani C; Passi A; Maifredi A; Tucci A; Capucci MA; Ruggeri G; Rossi G
Cancer; 2019 May; 125(10):1674-1682. PubMed ID: 30707758
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
